A Houston founder is introducing you to ema — a GPT-based chat platform and your new best friend in women's health. Photo via Canva

Amanda Ducach set out to create a platform where mothers could connect with each other socially, but when she launched SocialMama just ahead of a global pandemic, she soon learned there was a bigger market need for access to information surrounding women's health — from fertility to menopause.

After pivoting her femtech platform to include women's health experts, she realized her technology wasn't able to completely support growing user base. The platform, which was called SocialMama, saw users engaging with experts in similar ways — and as Ducach looked into growing the platforms users, she realized that 24/7 access to experts was going to be hard to scale.

"We noticed that most of these conversations were repetitive," Ducach tells InnovationMap. "You had women asking an expert about tracking ovulation a hundred times a day. Having an OBGYN answer that question a hundred times a day was crazy and just not scalable."

Ducach says that about 16 months ago, her team took a step back to recreate the platform incorporating GPT technology. GPT stands for generative pre-trained transformer, and is a family of artificial intelligence language models most recently made popular but ChatGPT developed by OpenAI.

Now, after building out the platform, Ducach's company has rebranded to ema. The AI-based chat tool — named from the three letters in the middle of "female" — is meant to feel like texting "your childhood best friend who became an OBGYN physician," Ducach says. Not only can the chat provide crucial medical information, but it has a memory and can pick up conversations where they left off to be a constant resource to users.

The new platform, deemed ema, operates as an AI-based chat for women to engage with. Screenshot courtesy of ema

"Ema can answer everything from, 'how do I improve my baby's latch,' to 'how to I get a diabetic-friendly brownie recipe,' to 'give me an affirmation that's spoken like Snoop Dog because I'm feeling sad today,'" Ducach says.

Ducach first described the evolution of the company to AI-based communication last summer on the Houston Innovators Podcast. Now, the platform is gearing up for its launch next month and plans to raise seed funding this year to double her current team of 10 people to support the company's growth. Ducach, who was accepted into the Techstars Austin program in 2021, also says she's looking for more beta users in the meantime, and those interested should reach out to her or her team.

Ultimately, Ducach says the mission of ema is to democratize access to women's health care so that women feel supported and just a few taps away from important information.

"Barriers to care for women who face socioeconomic disparities is where you see the need for change," Ducach says. "For us, it's reducing those barriers of care. Ema is always in your pocket. You have access to her 24/7. The way that ema is really structured and her purpose is to catch red flags so that we can then help the female user get to positive health outcomes."

Amanda Ducach founded the company in 2019. Photo via Twitter

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.